REG - Inspiration Health - Change of Website

Inspiration HealthcareAnnouncement

01/03/2023 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230301:nRSA3810Ra&default-theme=true

RNS Number : 3810R  Inspiration Healthcare Group PLC  01 March 2023

 

1 March 2023

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

Change of Website

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology
company, announces the launch of its new Company website
www.inspirationhealthcaregroup.com (http://www.inspirationhealthcaregroup.com)
. The new website has replaced and streamlined the former websites for the
Group and its three subsidiary companies; Inspiration Healthcare Ltd, SLE Ltd,
and Viomedex Ltd to ensure all product content is unified under the Group
brand on a single website.

 

 The new website contains all information required pursuant to AIM Rule 26.

 

 Inspiration Healthcare Group plc                                              Tel: +44  (0)330 175 0000

 Neil Campbell, Chief Executive Officer

 Cenkos Securities plc (Nominated Adviser & Broker)                            Tel: +44 (0)207 397 8900
 Stephen Keys, Katy Birkin, Dan Hodkinson

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780
 Anna Dunphy/Stephanie Cuthbert

 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology
for use in neonatal intensive care & operating theatres. The Company
provides high quality innovative products to patients around the world which
help to improve patient outcomes and it actively invests in innovative product
opportunities and disruptive technologies.

 

The Company has key own brand products that can be used within the first days
of life to help premature and sick babies; helping resuscitation and
stabilisation in the first moments of life through to preventing brain damage
and both invasive and non-invasive respiratory support in terms of capital
equipment and disposable medical devices. Additionally, the Company has its
own range of products for maintaining normothermia pre, during and
post-surgery.

 

Since September 2019, the Company has acquired Vio Holdings a designer,
manufacturer and supplier of single use respiratory products and sterile
medical consumables and S.L.E., a leading designer, manufacturer and global
provider of neonatal ventilation products.  The Group generates approximately
58% of its revenues from export markets and more than half of its revenues
come from its own-branded products.

 

With product availability actively promoted to over 80 countries through a
distribution network, Inspiration Healthcare's success has been built on
continuous innovation, excellent customer service and an inherent commitment
to improving patient outcomes, working in close collaboration with key opinion
leaders across the globe.

 

In the UK and Ireland, the Group has direct sales teams selling Group Branded
and complementary products from third parties, with an additional range of
home healthcare products.  This is supported by Technical Support for planned
preventative maintenance and emergency assistance.

 

The Group operates from various sites in the UK for R&D, Marketing and
operations with manufacturing based in Croydon (south London) and Hailsham
(East Sussex).  The Group's Head Office is located in Crawley, a short
distance from London's Gatwick Airport.

 

Further information on Inspiration Healthcare can be found at
www.inspirationhealthcaregroup.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.inspirationhealthcaregroup.com&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=qE1yMNvX8OUmO7FV4SLAuFx81K4O8nrPcCbRUEpXKXA&m=AsjyE6dIARHBI2srhLsFJ1FNF6k58JhlTqEi2mPCslc&s=6wj1SWY-lTlBNmgGCdsoxZp8j2t1ASo3qHBlM01KC4Q&e=)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZVLFLXLLLBBD